| Deficiencies in health-related quality-of-life assessment and reporting: a systematic review of oncology randomized phase III trials published between 2012 and 2016 L Marandino, A La Salvia, C Sonetto, E De Luca, D Pignataro, C Zichi, ... Annals of oncology 29 (12), 2288-2295, 2018 | 78 | 2018 |
| Metformin use is associated with longer progression-free survival of patients with diabetes and pancreatic neuroendocrine tumors receiving everolimus and/or somatostatin analogues S Pusceddu, C Vernieri, M Di Maio, R Marconcini, F Spada, S Massironi, ... Gastroenterology 155 (2), 479-489. e7, 2018 | 68 | 2018 |
| The correlation between immune subtypes and consensus molecular subtypes in colorectal cancer identifies novel tumour microenvironment profiles, with prognostic and therapeutic … B Soldevilla, C Carretero-Puche, G Gomez-Lopez, F Al-Shahrour, ... European Journal of Cancer 123, 118-129, 2019 | 62 | 2019 |
| Neuroendocrine breast carcinoma: a rare but challenging entity E Trevisi, A La Salvia, L Daniele, MP Brizzi, G De Rosa, GV Scagliotti, ... Medical Oncology 37, 1-8, 2020 | 42 | 2020 |
| Impact of total neoadjuvant therapy vs. standard chemoradiotherapy in locally advanced rectal cancer: a systematic review and meta-analysis of randomized trials MC Riesco-Martinez, C Fernandez-Martos, C Gravalos-Castro, ... Cancers 12 (12), 3655, 2020 | 38 | 2020 |
| Quality of life analysis in lung cancer: a systematic review of phase III trials published between 2012 and 2018 ML Reale, E De Luca, P Lombardi, L Marandino, C Zichi, D Pignataro, ... Lung Cancer 139, 47-54, 2020 | 38 | 2020 |
| High interlaboratory and interobserver agreement of somatostatin receptor immunohistochemical determination and correlation with response to somatostatin analogs A Kasajima, M Papotti, W Ito, MP Brizzi, A La Salvia, I Rapa, T Tachibana, ... Human pathology 72, 144-152, 2018 | 38 | 2018 |
| HER2-targeted therapy: an emerging strategy in advanced colorectal cancer A La Salvia, V Lopez-Gomez, R Garcia-Carbonero Expert opinion on investigational drugs 28 (1), 29-38, 2019 | 36 | 2019 |
| Nonconventional doses of somatostatin analogs in patients with progressing well-differentiated neuroendocrine tumor G Lamberti, A Faggiano, N Brighi, S Tafuto, T Ibrahim, MP Brizzi, ... The Journal of Clinical Endocrinology & Metabolism 105 (1), 194-200, 2020 | 34 | 2020 |
| Treatment of patients with metastatic colorectal cancer in a real-world scenario: probability of receiving second and further lines of therapy and description of clinical benefit M Tampellini, M Di Maio, C Baratelli, L Anania, MP Brizzi, C Sonetto, ... Clinical colorectal cancer 16 (4), 372-376, 2017 | 26 | 2017 |
| Targeted cancer therapy: what’s new in the field of neuroendocrine neoplasms? A La Salvia, P Espinosa-Olarte, MDC Riesco-Martinez, B Anton-Pascual, ... Cancers 13 (7), 1701, 2021 | 22 | 2021 |
| Quality of life assessment and reporting in colorectal cancer: a systematic review of phase III trials published between 2012 and 2018 P Lombardi, L Marandino, E De Luca, C Zichi, ML Reale, D Pignataro, ... Critical reviews in oncology/hematology 146, 102877, 2020 | 20 | 2020 |
| A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors S Pusceddu, F Barretta, A Trama, L Botta, M Milione, R Buzzoni, ... Endocrine-Related Cancer 25 (6), 607-618, 2018 | 20 | 2018 |
| Oxidized lipids in the metabolic profiling of neuroendocrine tumors–Analytical challenges and biological implications Á López-López, J Godzien, B Soldevilla, A Gradillas, Á López-Gonzálvez, ... Journal of Chromatography A 1625, 461233, 2020 | 17 | 2020 |
| Chemotherapy in NEN: still has a role? P Espinosa-Olarte, A La Salvia, MC Riesco-Martinez, B Anton-Pascual, ... Reviews in Endocrine and Metabolic Disorders 22 (3), 595-614, 2021 | 15 | 2021 |
| The role and expression of angiogenesis-related miRNAs in gastric cancer M Giuppi, A La Salvia, J Evangelista, M Ghidini Biology 10 (2), 146, 2021 | 14 | 2021 |
| Quality-Of-Life assessment and reporting in prostate cancer: systematic review of phase 3 trials testing anticancer drugs published between 2012 and 2018 L Marandino, E De Luca, C Zichi, P Lombardi, ML Reale, D Pignataro, ... Clinical Genitourinary Cancer 17 (5), 332-347. e2, 2019 | 14 | 2019 |
| Intercalated chemotherapy and epidermal growth factor receptor inhibitors for patients with advanced non–small-cell lung cancer: a systematic review and meta-analysis A La Salvia, A Rossi, D Galetta, E Gobbini, E De Luca, S Novello, ... Clinical lung cancer 18 (1), 23-33. e1, 2017 | 14 | 2017 |
| Are markers of systemic inflammatory response useful in the management of patients with neuroendocrine neoplasms? E Giannetta, A La Salvia, L Rizza, G Muscogiuri, S Campione, C Pozza, ... Frontiers in Endocrinology 12, 672499, 2021 | 12 | 2021 |
| Chemotherapy and intercalated gefitinib or erlotinib in the treatment of advanced non-small-cell lung cancer A Rossi, A La Salvia, M Di Maio Expert Review of Respiratory Medicine 11 (3), 171-180, 2017 | 12 | 2017 |
